Melbourne biotech PolyActiva says it hopes to be the next Cochlear by selling its eye drug dispensing system to millions ...

Swiss eye care specialist Alcon (SIX/NYSE: ALC) yesterday revealed the US Food and Drug Administration (FDA) has approved ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

Melbourne-based biotech firm PolyActiva, which has spent 15 years developing an eye-implant technology to treat glaucoma, has ...

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...

Since launching in late 2023, the NRF has backed companies, including $32 million for Harrison.ai, $ 13 million for Quantum Brilliance, and $25 million for Myriota. Despite that, the PolyActiva deal ...

The international biotechnology company BeiGene is moving its legal headquarters from the Cayman Islands to Basel. In ...

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

Analysts have set 12-month price targets for Ocular Therapeutix, revealing an average target of $15.71, a high estimate of ...

Story April 10 - Opthea: Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton crew to save money. Story April ...